Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Neoplasms of the CNS

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 128 articles:
HTML format



Single Articles


    October 2021
  1. LIU R, Dai W, Wu A, Li Y, et al
    CircCDC45 promotes the malignant progression of glioblastoma by modulating the miR-485-5p/CSF-1 axis.
    BMC Cancer. 2021;21:1090.
    PubMed     Abstract available


    September 2021
  2. CHENG S, Yang L, Dai X, Wang J, et al
    The risk and prognostic factors for brain metastases in esophageal cancer patients: an analysis of the SEER database.
    BMC Cancer. 2021;21:1057.
    PubMed     Abstract available


  3. MAKINO Y, Arakawa Y, Yoshioka E, Shofuda T, et al
    Infrequent RAS mutation is not associated with specific histological phenotype in gliomas.
    BMC Cancer. 2021;21:1025.
    PubMed     Abstract available


  4. TYLDESLEY-MARSHALL N, Greenfield S, Neilson SJ, English M, et al
    The role of Magnetic Resonance Images (MRIs) in coping for patients with brain tumours and their parents: a qualitative study.
    BMC Cancer. 2021;21:1013.
    PubMed     Abstract available


  5. MIKIC N, Poulsen FR, Kristoffersen KB, Laursen RJ, et al
    Study protocol for OptimalTTF-2: enhancing Tumor Treating Fields with skull remodeling surgery for first recurrence glioblastoma: a phase 2, multi-center, randomized, prospective, interventional trial.
    BMC Cancer. 2021;21:1010.
    PubMed     Abstract available


    August 2021
  6. HACKSHAW MD, Danysh HE, Henderson M, Wang E, et al
    Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review.
    BMC Cancer. 2021;21:967.
    PubMed     Abstract available


  7. LI Y, Guo D
    Genome-wide profiling of alternative splicing in glioblastoma and their clinical value.
    BMC Cancer. 2021;21:958.
    PubMed     Abstract available


  8. KIM YJ, Oh H, Lee SJ, Kim KM, et al
    Prognostic significance of the postoperative prognostic nutritional index in patients with glioblastoma: a retrospective study.
    BMC Cancer. 2021;21:942.
    PubMed     Abstract available


    July 2021
  9. GINZAC A, Dupic G, Brun L, Molnar I, et al
    Preoperative stereotactic radiosurgery for brain metastases: the STEP study protocol for a multicentre, prospective, phase-II trial.
    BMC Cancer. 2021;21:864.
    PubMed     Abstract available


  10. ASANO K, Fumoto T, Matsuzaka M, Hasegawa S, et al
    Combination chemoradiotherapy with temozolomide, vincristine, and interferon-beta might improve outcomes regardless of O6-methyl-guanine-DNA-methyltransferase (MGMT) promoter methylation status in newly glioblastoma.
    BMC Cancer. 2021;21:867.
    PubMed     Abstract available


  11. SYAFRUDDIN SE, Nazarie WFWM, Moidu NA, Soon BH, et al
    Integration of RNA-Seq and proteomics data identifies glioblastoma multiforme surfaceome signature.
    BMC Cancer. 2021;21:850.
    PubMed     Abstract available


  12. HUANG T, Chen Y, Zeng Y, Xu C, et al
    Long non-coding RNA PSMA3-AS1 promotes glioma progression through modulating the miR-411-3p/HOXA10 pathway.
    BMC Cancer. 2021;21:844.
    PubMed     Abstract available


  13. SHEN H, Deng G, Chen Q, Qian J, et al
    The incidence, risk factors and predictive nomograms for early death of lung cancer with synchronous brain metastasis: a retrospective study in the SEER database.
    BMC Cancer. 2021;21:825.
    PubMed     Abstract available


    June 2021
  14. LU J, Peng Y, Huang R, Feng Z, et al
    Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
    BMC Cancer. 2021;21:723.
    PubMed     Abstract available


  15. TU Z, Xiong H, Qiu Y, Li G, et al
    Limited recurrence distance of glioblastoma under modern radiotherapy era.
    BMC Cancer. 2021;21:720.
    PubMed     Abstract available


  16. ZHU W, Zhao H, Xu F, Huang B, et al
    The lipid-lowering drug fenofibrate combined with si-HOTAIR can effectively inhibit the proliferation of gliomas.
    BMC Cancer. 2021;21:664.
    PubMed     Abstract available


  17. MOON HH, Kim HS, Park JE, Kim YH, et al
    Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
    BMC Cancer. 2021;21:654.
    PubMed     Abstract available


    May 2021
  18. SHAN Q, Shi J, Wang X, Guo J, et al
    A new nomogram and risk classification system for predicting survival in small cell lung cancer patients diagnosed with brain metastasis: a large population-based study.
    BMC Cancer. 2021;21:640.
    PubMed     Abstract available


  19. ZHU J, Wang H, Sun Q, Ji X, et al
    Correction to: Nrf2 is required to maintain the self-renewal of glioma stem cells.
    BMC Cancer. 2021;21:582.
    PubMed    


  20. MILLS MN, Naz A, Thawani C, Walker C, et al
    Capecitabine and stereotactic radiation in the management of breast cancer brain metastases.
    BMC Cancer. 2021;21:552.
    PubMed     Abstract available


  21. MAJCHRZAK-CELINSKA A, Misiorek JO, Kruhlenia N, Przybyl L, et al
    COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/beta-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
    BMC Cancer. 2021;21:493.
    PubMed     Abstract available


    April 2021
  22. YAMAMURA J, Kamigaki S, Fujita J, Osato H, et al
    New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.
    BMC Cancer. 2021;21:476.
    PubMed     Abstract available


  23. XU B, Huo Z, Huang H, Ji W, et al
    The expression and prognostic value of the epidermal growth factor receptor family in glioma.
    BMC Cancer. 2021;21:451.
    PubMed     Abstract available


  24. AMIN S, Baine M, Meza J, Lin C, et al
    The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type.
    BMC Cancer. 2021;21:387.
    PubMed     Abstract available


  25. RADES D, Witteler J, Olbrich D, Trillenberg P, et al
    A prospective interventional study evaluating seizure activity during a radiotherapy course for high-grade gliomas (SURF-ROGG).
    BMC Cancer. 2021;21:386.
    PubMed     Abstract available


    March 2021
  26. KUO CS, Tung PH, Huang AC, Wang CC, et al
    A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
    BMC Cancer. 2021;21:309.
    PubMed     Abstract available


  27. XI J, Hassan B, Katumba RGN, Khaddour K, et al
    The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma.
    BMC Cancer. 2021;21:285.
    PubMed     Abstract available


  28. KIANG KM, Chan AA, Leung GK
    Secondary gliosarcoma: the clinicopathological features and the development of a patient-derived xenograft model of gliosarcoma.
    BMC Cancer. 2021;21:265.
    PubMed     Abstract available


  29. ZHANG C, Liu H, Xu P, Tan Y, et al
    Identification and validation of a five-lncRNA prognostic signature related to Glioma using bioinformatics analysis.
    BMC Cancer. 2021;21:251.
    PubMed     Abstract available


  30. RYDEN I, Thurin E, Carstam L, Smits A, et al
    Psychotropic and anti-epileptic drug use, before and after surgery, among patients with low-grade glioma: a nationwide matched cohort study.
    BMC Cancer. 2021;21:248.
    PubMed     Abstract available


  31. MILLS MN, Walker C, Thawani C, Naz A, et al
    Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases.
    BMC Cancer. 2021;21:223.
    PubMed     Abstract available


  32. MASALHA W, Daka K, Woerner J, Pompe N, et al
    Metabolic alterations in meningioma reflect the clinical course.
    BMC Cancer. 2021;21:211.
    PubMed     Abstract available


    February 2021
  33. ZHANG Y, Zou D, Yin J, Zhang L, et al
    Changes in cerebrospinal fluid interleukin-10 levels display better performance in predicting disease relapse than conventional magnetic resonance imaging in primary central nervous system lymphoma.
    BMC Cancer. 2021;21:183.
    PubMed     Abstract available


  34. KHAN M, Zhao Z, Arooj S, Liao G, et al
    Bevacizumab for radiation necrosis following radiotherapy of brain metastatic disease: a systematic review & meta-analysis.
    BMC Cancer. 2021;21:167.
    PubMed     Abstract available


  35. KEOGH RJ, Aslam R, Hennessy MA, Coyne Z, et al
    One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre.
    BMC Cancer. 2021;21:140.
    PubMed     Abstract available


  36. GUAN Y, Xiong J, Pan M, Shi W, et al
    Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience.
    BMC Cancer. 2021;21:123.
    PubMed     Abstract available


    January 2021
  37. LIU G, Liu D, Huang J, Li J, et al
    Comprehensive analysis of ceRNA network related to lincRNA in glioblastoma and prediction of clinical prognosis.
    BMC Cancer. 2021;21:98.
    PubMed     Abstract available


  38. LIU FM, Gao YF, Kong Y, Guan Y, et al
    The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET.
    BMC Cancer. 2021;21:83.
    PubMed     Abstract available


  39. WEN J, Chen W, Zhu Y, Zhang P, et al
    Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis.
    BMC Cancer. 2021;21:81.
    PubMed     Abstract available


  40. CHEN B, Chen C, Zhang Y, Xu J, et al
    Recent incidence trend of elderly patients with glioblastoma in the United States, 2000-2017.
    BMC Cancer. 2021;21:54.
    PubMed     Abstract available


  41. WANG Y, Zhang Y, Hong Y, Zeng P, et al
    Advance directives and end-of-life care: knowledge and preferences of patients with brain Tumours from Anhui, China.
    BMC Cancer. 2021;21:25.
    PubMed     Abstract available


    December 2020
  42. HIGGINS DMO, Caliva M, Schroeder M, Carlson B, et al
    Semaphorin 3A mediated brain tumor stem cell proliferation and invasion in EGFRviii mutant gliomas.
    BMC Cancer. 2020;20:1213.
    PubMed     Abstract available


  43. COLLINS DC, Sundar R, Constantinidou A, Dolling D, et al
    Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease.
    BMC Cancer. 2020;20:1210.
    PubMed     Abstract available


    November 2020
  44. YU X, Wang Y, Yuan Z, Yu H, et al
    Benefit of dosimetry distribution for patients with multiple brain metastases from non-small cell lung cancer by a Cyberknife stereotactic radiosurgery (SRS) system.
    BMC Cancer. 2020;20:1144.
    PubMed     Abstract available


  45. LI X, Meng Y
    Analyses of metastasis-associated genes in IDH wild-type glioma.
    BMC Cancer. 2020;20:1114.
    PubMed     Abstract available


  46. ZHU Z, Lan Y, Wang L, Ge J, et al
    A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
    BMC Cancer. 2020;20:1072.
    PubMed     Abstract available


  47. AFTAHY AK, Barz M, Krauss P, Liesche F, et al
    Intraventricular neuroepithelial tumors: surgical outcome, technical considerations and review of literature.
    BMC Cancer. 2020;20:1060.
    PubMed     Abstract available


    October 2020
  48. CHIA BSH, Leong JY, Ong ALK, Lim C, et al
    Randomised prospective phase II trial in multiple brain metastases comparing outcomes between hippocampal avoidance whole brain radiotherapy with or without simultaneous integrated boost: HA-SIB-WBRT study protocol.
    BMC Cancer. 2020;20:1045.
    PubMed     Abstract available


  49. DING X, Yang L, Geng X, Zou Y, et al
    CircRNAs as potential biomarkers for the clinicopathology and prognosis of glioma patients: a meta-analysis.
    BMC Cancer. 2020;20:1005.
    PubMed     Abstract available


  50. GUENOLE M, Lucia F, Bourbonne V, Dissaux G, et al
    Impact of concomitant systemic treatments on toxicity and intracerebral response after stereotactic radiotherapy for brain metastases.
    BMC Cancer. 2020;20:991.
    PubMed     Abstract available


  51. FENG J, Ouyang Y, Xu D, He Q, et al
    Genetic variants in MIR17HG affect the susceptibility and prognosis of glioma in a Chinese Han population.
    BMC Cancer. 2020;20:976.
    PubMed     Abstract available


  52. HONG KT, Lee DH, Kim BK, An HY, et al
    Treatment outcome and long-term follow-up of central nervous system germ cell tumor using upfront chemotherapy with subsequent photon or proton radiation therapy: a single tertiary center experience of 127 patients.
    BMC Cancer. 2020;20:979.
    PubMed     Abstract available


  53. BLECKMANN A, Kirchner B, Nietert M, Peeck M, et al
    Impact of pre-OP independence in patients with limited brain metastases on long-term survival.
    BMC Cancer. 2020;20:973.
    PubMed     Abstract available


    September 2020
  54. WANG J, Tong L, Lin G, Wang H, et al
    Immunological and clinicopathological characteristics of C1RL in 2120 glioma patients.
    BMC Cancer. 2020;20:931.
    PubMed     Abstract available


  55. VUONG HG, Nguyen TQ, Ngo TNM, Nguyen HC, et al
    The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis.
    BMC Cancer. 2020;20:897.
    PubMed     Abstract available


  56. WANG J, Liu Z, Pang Q, Zhang T, et al
    Prognostic analysis of patients with non-small cell lung cancer harboring exon 19 or 21 mutation in the epidermal growth factor gene and brain metastases.
    BMC Cancer. 2020;20:837.
    PubMed     Abstract available


  57. DU F, Hou Q
    SNHG17 drives malignant behaviors in astrocytoma by targeting miR-876-5p/ERLIN2 axis.
    BMC Cancer. 2020;20:839.
    PubMed     Abstract available


    August 2020
  58. COSTE A, Bailey HD, Kartal-Kaess M, Renella R, et al
    Parental occupational exposure to pesticides and risk of childhood cancer in Switzerland: a census-based cohort study.
    BMC Cancer. 2020;20:819.
    PubMed     Abstract available


  59. HEILAND DH, Ohle R, Cipriani D, Franco P, et al
    Characterization of longitudinal transformation of T2-hyperintensity in oligodendroglioma.
    BMC Cancer. 2020;20:818.
    PubMed     Abstract available


  60. BEN-ZION BERLINER M, Katz LH, Derazne E, Levine H, et al
    Height as a risk factor in meningioma: a study of 2 million Israeli adolescents.
    BMC Cancer. 2020;20:786.
    PubMed     Abstract available


  61. FRANCESCHI E, Minichillo S, Mura A, Tosoni A, et al
    Adjuvant chemotherapy in average-risk adult medulloblastoma patients improves survival: a long term study.
    BMC Cancer. 2020;20:755.
    PubMed     Abstract available


  62. WANG C, Liu S, Peng L, Zhang K, et al
    Correction to: Permanent iodine-125 brachytherapy for patients with progressive or recurrent high-grade gliomas.
    BMC Cancer. 2020;20:736.
    PubMed     Abstract available


    July 2020
  63. SHEN CC, Cheng WY, Lee CH, Dai XJ, et al
    Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment.
    BMC Cancer. 2020;20:709.
    PubMed     Abstract available


  64. HEUSER VD, Kiviniemi A, Lehtinen L, Munthe S, et al
    Multiple formin proteins participate in glioblastoma migration.
    BMC Cancer. 2020;20:710.
    PubMed     Abstract available


  65. LOCSEI Z, Farkas R, Borbasne Farkas K, Sebestyen K, et al
    Assessment of the results and hematological side effects of 3D conformal and IMRT/ARC therapies delivered during craniospinal irradiation of childhood tumors with a follow-up period of five years.
    BMC Cancer. 2020;20:702.
    PubMed     Abstract available


  66. OUYANG W, Yu J, Zhou Y, Hu J, et al
    Risk factors of metachronous brain metastasis in patients with EGFR-mutated advanced non-small cell lung cancer.
    BMC Cancer. 2020;20:699.
    PubMed     Abstract available


  67. ZHAO Y, He JY, Cui JZ, Meng ZQ, et al
    Detection of genes mutations in cerebrospinal fluid circulating tumor DNA from neoplastic meningitis patients using next generation sequencing.
    BMC Cancer. 2020;20:690.
    PubMed     Abstract available


  68. ZHANG F, Liu R, Zhang H, Liu C, et al
    Suppressing Dazl modulates tumorigenicity and stemness in human glioblastoma cells.
    BMC Cancer. 2020;20:673.
    PubMed     Abstract available


  69. GAN C, Pierscianek D, El Hindy N, Ahmadipour Y, et al
    The predominant expression of cancer stem cell marker ALDH1A3 in tumor infiltrative area is associated with shorter overall survival of human glioblastoma.
    BMC Cancer. 2020;20:672.
    PubMed     Abstract available


  70. LIN J, Yu L, Fu Y, Chen H, et al
    A refractory case of CDK4-amplified spinal astrocytoma achieving complete response upon treatment with a Palbociclib-based regimen:a case report.
    BMC Cancer. 2020;20:630.
    PubMed     Abstract available


  71. MEZEI T, Hajdu M, Czigleczki G, Lotz G, et al
    Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: a case report and literature review.
    BMC Cancer. 2020;20:615.
    PubMed     Abstract available


    June 2020
  72. MEHTA P, Janssen S, Fahlbusch FB, Schmid SM, et al
    Sparing the hippocampus and the hypothalamic- pituitary region during whole brain radiotherapy: a volumetric modulated arc therapy planning study.
    BMC Cancer. 2020;20:610.
    PubMed     Abstract available


  73. XU T, Zhang X, Zhang S, Liu C, et al
    Imaging features and prognostic value of (18)F-FDG PET/CT detection of soft-tissue metastasis from lung cancer: a retrospective study.
    BMC Cancer. 2020;20:596.
    PubMed     Abstract available


  74. WANG C, Liu S, Peng L, Zhang K, et al
    Permanent iodine-125 brachytherapy for patients with progressive or recurrent high-grade gliomas.
    BMC Cancer. 2020;20:591.
    PubMed     Abstract available


  75. DING L, Zhang F, He Q, Li Z, et al
    Differentiation of suprasellar meningiomas from non-functioning pituitary macroadenomas by (18)F-FDG and (13)N-Ammonia PET/CT.
    BMC Cancer. 2020;20:564.
    PubMed     Abstract available


  76. LOW SYY, Bte Syed Sulaiman N, Tan EEK, Ng LP, et al
    Cerebrospinal fluid cytokines in metastatic group 3 and 4 medulloblastoma.
    BMC Cancer. 2020;20:554.
    PubMed     Abstract available


  77. CAI Z, Yang S, Li X, Chen F, et al
    Viral infection and glioma: a meta-analysis of prognosis.
    BMC Cancer. 2020;20:549.
    PubMed     Abstract available


  78. GROSU AL, Frings L, Bentsalo I, Oehlke O, et al
    Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging (HIPPORAD) - a phase II prospective randomized multicenter trial (NOA-14, ARO 2015-3, DKTK-ROG).
    BMC Cancer. 2020;20:532.
    PubMed     Abstract available


  79. BARCISZEWSKA AM
    Total DNA methylation as a biomarker of DNA damage and tumor malignancy in intracranial meningiomas.
    BMC Cancer. 2020;20:509.
    PubMed     Abstract available


  80. HOWELL AE, Robinson JW, Wootton RE, McAleenan A, et al
    Testing for causality between systematically identified risk factors and glioma: a Mendelian randomization study.
    BMC Cancer. 2020;20:508.
    PubMed     Abstract available


  81. DEVECKA M, Duma MN, Wilkens JJ, Kampfer S, et al
    Craniospinal irradiation(CSI) in patients with leptomeningeal metastases: risk-benefit-profile and development of a prognostic score for decision making in the palliative setting.
    BMC Cancer. 2020;20:501.
    PubMed     Abstract available


    May 2020
  82. BUCKSCH K, Zachariae S, Aretz S, Buttner R, et al
    Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: a prospective cohort study.
    BMC Cancer. 2020;20:460.
    PubMed     Abstract available


  83. CORELL A, Ferreyra Vega S, Hoefling N, Carstam L, et al
    The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study.
    BMC Cancer. 2020;20:450.
    PubMed     Abstract available


  84. WHITMIRE P, Rickertsen CR, Hawkins-Daarud A, Carrasco E Jr, et al
    Sex-specific impact of patterns of imageable tumor growth on survival of primary glioblastoma patients.
    BMC Cancer. 2020;20:447.
    PubMed     Abstract available


  85. KIESEL B, Thome CM, Weiss T, Jakola AS, et al
    Perioperative imaging in patients treated with resection of brain metastases: a survey by the European Association of Neuro-Oncology (EANO) Youngsters committee.
    BMC Cancer. 2020;20:410.
    PubMed     Abstract available


  86. WAKUDA K, Yamaguchi H, Kenmotsu H, Fukuda M, et al
    A phase II study of Osimertinib for patients with radiotherapy-naive CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L).
    BMC Cancer. 2020;20:370.
    PubMed     Abstract available


    April 2020
  87. MITSUYA K, Nakasu Y, Hayashi N, Deguchi S, et al
    Retrospective analysis of salvage surgery for local progression of brain metastasis previously treated with stereotactic irradiation: diagnostic contribution, functional outcome, and prognostic factors.
    BMC Cancer. 2020;20:331.
    PubMed     Abstract available


  88. TAMURA R, Morimoto Y, Kosugi K, Sato M, et al
    Correction to: Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series.
    BMC Cancer. 2020;20:301.
    PubMed     Abstract available


  89. SHAH N, Liu Z, Tallman RM, Mohammad A, et al
    Drug resistance occurred in a newly characterized preclinical model of lung cancer brain metastasis.
    BMC Cancer. 2020;20:292.
    PubMed     Abstract available


  90. FARIA GM, Soares IDP, D'Alincourt Salazar M, Amorim MR, et al
    Intranasal perillyl alcohol therapy improves survival of patients with recurrent glioblastoma harboring mutant variant for MTHFR rs1801133 polymorphism.
    BMC Cancer. 2020;20:294.
    PubMed     Abstract available


  91. FURUSE M, Kuwabara H, Ikeda N, Hattori Y, et al
    PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
    BMC Cancer. 2020;20:277.
    PubMed     Abstract available


    March 2020
  92. LU C, Liu J, Yao M, Li L, et al
    Downregulation of S100 calcium binding protein A12 inhibits the growth of glioma cells.
    BMC Cancer. 2020;20:261.
    PubMed     Abstract available


  93. NAWROCKI S, Sugajska A
    Study protocol: watchful observation of patients with limited small cell lung cancer instead of the PCI-prospective, multi-center one-arm study.
    BMC Cancer. 2020;20:231.
    PubMed     Abstract available


  94. WANG L, Ge J, Lan Y, Shi Y, et al
    Tumor mutational burden is associated with poor outcomes in diffuse glioma.
    BMC Cancer. 2020;20:213.
    PubMed     Abstract available


  95. BROWN NF, Ng SM, Brooks C, Coutts T, et al
    A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol.
    BMC Cancer. 2020;20:198.
    PubMed     Abstract available


  96. TAMURA R, Morimoto Y, Kosugi K, Sato M, et al
    Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series.
    BMC Cancer. 2020;20:196.
    PubMed     Abstract available


    February 2020
  97. LESUEUR P, Kao W, Leconte A, Geffrelot J, et al
    Stereotactic radiotherapy on brain metastases with recent hemorrhagic signal: STEREO-HBM, a two-step phase 2 trial.
    BMC Cancer. 2020;20:147.
    PubMed     Abstract available


  98. CHO I, Lee H, Yoon SE, Ryu KJ, et al
    Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.
    BMC Cancer. 2020;20:120.
    PubMed     Abstract available


  99. PATRIKIDOU A, Chaigneau L, Isambert N, Kitikidou K, et al
    Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA).
    BMC Cancer. 2020;20:117.
    PubMed     Abstract available


  100. TREUTWEIN M, Steger F, Loeschel R, Koelbl O, et al
    The influence of radiotherapy techniques on the plan quality and on the risk of secondary tumors in patients with pituitary adenoma.
    BMC Cancer. 2020;20:88.
    PubMed     Abstract available


    January 2020
  101. ANG SYL, Lee L, See AAQ, Ang TY, et al
    Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study.
    BMC Cancer. 2020;20:79.
    PubMed     Abstract available


  102. LIU K, Jiang G, Zhang A, Li Z, et al
    Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer.
    BMC Cancer. 2020;20:76.
    PubMed     Abstract available


  103. NAKANO T, Aoyama H, Saito H, Tanabe S, et al
    The neurocognitive function change criteria after whole-brain radiation therapy for brain metastasis, in reference to health-related quality of life changes: a prospective observation study.
    BMC Cancer. 2020;20:66.
    PubMed     Abstract available


  104. SRIVASTAVA C, Irshad K, Gupta Y, Sarkar C, et al
    NFsmall ka, CyrillicB is a critical transcriptional regulator of atypical cadherin FAT1 in glioma.
    BMC Cancer. 2020;20:62.
    PubMed     Abstract available


  105. UMPHLETT M, Shea S, Tome-Garcia J, Zhang Y, et al
    Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.
    BMC Cancer. 2020;20:47.
    PubMed     Abstract available


  106. LIANG J, Lv X, Lu C, Ye X, et al
    Prognostic factors of patients with Gliomas - an analysis on 335 patients with Glioblastoma and other forms of Gliomas.
    BMC Cancer. 2020;20:35.
    PubMed     Abstract available


  107. GE JJ, Li C, Qi SP, Xue FJ, et al
    Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study.
    BMC Cancer. 2020;20:24.
    PubMed     Abstract available


  108. ENRIQUEZ PEREZ J, Kopecky J, Visse E, Darabi A, et al
    Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
    BMC Cancer. 2020;20:7.
    PubMed     Abstract available


    December 2019
  109. PERREAULT S, Larouche V, Tabori U, Hawkin C, et al
    A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.
    BMC Cancer. 2019;19:1250.
    PubMed     Abstract available


  110. SUN C, Dai X, Zhao D, Wang H, et al
    Mesenchymal stem cells promote glioma neovascularization in vivo by fusing with cancer stem cells.
    BMC Cancer. 2019;19:1240.
    PubMed     Abstract available


  111. GANGEMI V, Mignogna C, Guzzi G, Lavano A, et al
    Impact of [(64)Cu][Cu(ATSM)] PET/CT in the evaluation of hypoxia in a patient with Glioblastoma: a case report.
    BMC Cancer. 2019;19:1197.
    PubMed     Abstract available


  112. DA COSTA AABA, Dos Santos ES, Cotrim DP, Pandolfi NC, et al
    Prognostic impact of platinum sensitivity in ovarian carcinoma patients with brain metastasis.
    BMC Cancer. 2019;19:1194.
    PubMed     Abstract available


  113. HAO Z, Guo D
    EGFR mutation: novel prognostic factor associated with immune infiltration in lower-grade glioma; an exploratory study.
    BMC Cancer. 2019;19:1184.
    PubMed     Abstract available


    November 2019
  114. ZHONG QY, Fan EX, Feng GY, Chen QY, et al
    A gene expression-based study on immune cell subtypes and glioma prognosis.
    BMC Cancer. 2019;19:1116.
    PubMed     Abstract available


  115. LI Z, Shen D, Zhang J, Zhang J, et al
    Relationship between WBRT total dose, intracranial tumor control, and overall survival in NSCLC patients with brain metastases - a single-center retrospective analysis.
    BMC Cancer. 2019;19:1104.
    PubMed     Abstract available


  116. YU W, Ren X, Hu C, Tan Y, et al
    Glioma SOX2 expression decreased after adjuvant therapy.
    BMC Cancer. 2019;19:1087.
    PubMed     Abstract available


  117. SALVUCCI M, Zakaria Z, Carberry S, Tivnan A, et al
    System-based approaches as prognostic tools for glioblastoma.
    BMC Cancer. 2019;19:1092.
    PubMed     Abstract available


  118. CHATURVEDI NK, Mahapatra S, Kesherwani V, Kling MJ, et al
    Role of protein arginine methyltransferase 5 in group 3 (MYC-driven) Medulloblastoma.
    BMC Cancer. 2019;19:1056.
    PubMed     Abstract available


  119. BAZAN F, Dobi E, Royer B, Curtit E, et al
    Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer.
    BMC Cancer. 2019;19:1029.
    PubMed     Abstract available


    October 2019
  120. CHEN YH, Chen YF, Chen CY, Shih JY, et al
    Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
    BMC Cancer. 2019;19:1006.
    PubMed     Abstract available


  121. STOPPEK AK, Kebir S, Junker A, Keyvani K, et al
    Simultaneous primary cancer occurrence of melanoma and pulmonary adenocarcinoma in leptomeningeal metastases: a case report.
    BMC Cancer. 2019;19:995.
    PubMed     Abstract available


  122. BRITO C, Azevedo A, Esteves S, Marques AR, et al
    Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    BMC Cancer. 2019;19:968.
    PubMed     Abstract available


    September 2019
  123. TAKASHIMA Y, Yoshimura T, Kano Y, Hayano A, et al
    Differential expression of N-linked oligosaccharides in methotrexate-resistant primary central nervous system lymphoma cells.
    BMC Cancer. 2019;19:910.
    PubMed     Abstract available


    August 2019
  124. GOMEZ-ACEVEDO H, Patterson JD, Sardar S, Gokden M, et al
    SMARC-B1 deficient sinonasal carcinoma metastasis to the brain with next generation sequencing data: a case report of perineural invasion progressing to leptomeningeal invasion.
    BMC Cancer. 2019;19:827.
    PubMed     Abstract available


    July 2019
  125. XI S, Sai K, Hu W, Wang F, et al
    Clinical significance of the histological and molecular characteristics of ependymal tumors: a single institution case series from China.
    BMC Cancer. 2019;19:717.
    PubMed     Abstract available


  126. LIU J, Jin B, Su H, Qu X, et al
    Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case report.
    BMC Cancer. 2019;19:702.
    PubMed     Abstract available


    June 2019
  127. ZAKRZEWSKA M, Gruszka R, Stawiski K, Fendler W, et al
    Expression-based decision tree model reveals distinct microRNA expression pattern in pediatric neuronal and mixed neuronal-glial tumors.
    BMC Cancer. 2019;19:544.
    PubMed     Abstract available


    May 2019
  128. VAN BUSSEL MTJ, Beijnen JH, Brandsma D
    Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review.
    BMC Cancer. 2019;19:519.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: